In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan.
Acinetobacter baumannii
/ drug effects
Anti-Bacterial Agents
/ pharmacology
Azabicyclo Compounds
/ pharmacology
Bacteremia
/ microbiology
Ceftazidime
/ pharmacology
Cephalosporins
/ pharmacology
Drug Combinations
Drug Resistance, Multiple, Bacterial
Humans
Imipenem
/ pharmacology
Microbial Sensitivity Tests
Pseudomonas aeruginosa
/ drug effects
Stenotrophomonas maltophilia
/ drug effects
Taiwan
Tazobactam
/ pharmacology
Cefiderocol
Journal
The Journal of antimicrobial chemotherapy
ISSN: 1460-2091
Titre abrégé: J Antimicrob Chemother
Pays: England
ID NLM: 7513617
Informations de publication
Date de publication:
01 02 2019
01 02 2019
Historique:
received:
02
07
2018
accepted:
17
09
2018
pubmed:
26
10
2018
medline:
8
5
2020
entrez:
26
10
2018
Statut:
ppublish
Résumé
We investigated the in vitro activities of cefiderocol, ceftazidime/avibactam, ceftolozane/tazobactam and other related drugs against imipenem-resistant Pseudomonas aeruginosa, imipenem-resistant Acinetobacter baumannii and Stenotrophomonas maltophilia isolates. Non-duplicated bacteraemia isolates (n = 300) of imipenem-resistant P. aeruginosa (n = 100), imipenem-resistant A. baumannii (n = 100) and S. maltophilia (n = 100) were evaluated. Imipenem-resistant P. aeruginosa and imipenem-resistant A. baumannii isolates were defined as isolates exhibiting imipenem MIC ≥8 mg/L, as determined using the VITEK 2 system. The MICs of 11 other antimicrobial agents for the isolates were determined by the broth microdilution method. Iron-depleted CAMHB was used to determine the MICs of cefiderocol. The rates of colistin resistance of imipenem-resistant P. aeruginosa and imipenem-resistant A. baumannii were 5% and 10%, respectively. The MIC90 values of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam, tigecycline and colistin were as follows: imipenem-resistant P. aeruginosa: 1, 4, 16, >4 and 2 mg/L; imipenem-resistant A. baumannii: 8, >64, >64, 4 and 2 mg/L; and S. maltophilia: 0.25, >64, >64, 2 and >8 mg/L, respectively. For imipenem-resistant A. baumannii isolates, the MICs of cefiderocol, ceftolozane/tazobactam and ceftazidime/avibactam were ≤4 mg/L for 88%, 8% and 1% of the isolates, respectively. Cefiderocol MICs were ≤4 mg/L for the five colistin-resistant imipenem-resistant P. aeruginosa isolates and 70% of the 10 colistin-resistant imipenem-resistant A. baumannii isolates. Cefiderocol exhibited more potent in vitro activity than ceftolozane/tazobactam and ceftazidime/avibactam against imipenem-resistant P. aeruginosa, imipenem-resistant A. baumannii and S. maltophilia isolates.
Identifiants
pubmed: 30357343
pii: 5144002
doi: 10.1093/jac/dky425
doi:
Substances chimiques
Anti-Bacterial Agents
0
Azabicyclo Compounds
0
Cephalosporins
0
Drug Combinations
0
avibactam, ceftazidime drug combination
0
ceftolozane, tazobactam drug combination
0
Imipenem
71OTZ9ZE0A
Ceftazidime
9M416Z9QNR
Tazobactam
SE10G96M8W
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM